On New Year's Eve, a Maryland man who'd run heavy machinery for four decades woke up and his right eye had gone dark. A year later, still on his weekly Ozempic shot, the left one followed. This is GLP-1 Daily, and that story leads us into new research on how fast this rare eye condition can reach the second eye in people taking GLP-1s. After that, the paperwork gap in Medicare's fifty-dollar Bridge program, the pharmacists watching patients pay cash even when insurance would be cheaper, the World Health Organization's first-ever rules on treating childhood obesity, and a first for South Korea's drug regulator. One tap on follow, and we'll be back in your ears before you know it.
The American Academy of Ophthalmology, in a release on research presented at its annual meeting:
The difference was striking. Among GLP-1 users, 56.8 percent of second-eye events occurred within six months, compared with 40.6 percent among those not taking the medication. In the researchers' statistical model, the shift toward early rather than late events was about 1.98 times as strong in the GLP-1 group.
Quick definition. NAION is a sudden, painless loss of vision when the optic nerve doesn't get enough blood. We covered a doctor's warning about this so-called eye stroke back on Monday, September twenty-eighth. This is new data, and a different question: not whether it happens, but how fast the second eye goes. The setup. Researchers searched the Epic Cosmos health-record database for second-eye events from 2015 to 2025, about fourteen hundred forty GLP-1 users against roughly twenty thousand seven hundred non-users. Now the caveats, and the authors name them first. The GLP-1 users had higher average A1C, by one to one point four points, so worse diabetes could explain some or all of the gap. The data were aggregated, so this is an association, not cause and effect. And it's a meeting presentation, not a peer-reviewed paper yet. Meanwhile the courtroom is filling up. Medscape reports the federal eye-injury litigation reached two hundred forty-seven cases as of October, up from twenty-nine in January. European regulators raised NAION as a very rare possible side effect of semaglutide more than fifteen months ago. U.S. labels for Ozempic and Wegovy still say nothing about it. So a patient in Milan gets a warning that a patient in Maryland doesn't. The other side, per NPR's reporting Wednesday: Novo Nordisk says NAION and other serious conditions are exceedingly rare in clinical trials, that the FDA hasn't requested label changes, and that the lawsuits are without merit. Lawyers for Lilly and Novo note that diabetes and sleep apnea can raise NAION risk on their own. NAION may affect about one in ten thousand people. The study's co-author, Ashley Tin, is direct: don't stop your medication over this. But sudden, painless vision loss or a new blind spot means an eye doctor promptly, and then a conversation with whoever prescribed your GLP-1. If you've already had NAION in one eye, make sure your ophthalmologist knows you're on one.
T. Joseph Mattingly, Rena Conti and Sean Sullivan, writing in Health Affairs:
Access to the Bridge program may be hindered for beneficiaries who began GLP-1 treatment for weight management outside the traditional insurance system, where dispensing records are fragmented or inaccessible. The challenge is particularly acute among patients who initiated cash-pay therapy through telehealth platforms or compounding pharmacies and later seek treatment from a different clinician or are transitioning into Medicare.
Yesterday it was sleep apnea knocking people out of the Medicare GLP-1 Bridge, the fifty-dollar copay pilot that opened July first. Today, a second crack, and it hits the people who were already doing the work. Two national pharmacy chains each filled roughly a hundred thousand Bridge prescriptions in the first two months, so this is a program at scale. Here's the mechanism. Prescribers attest to your BMI when you started a GLP-1, which is meant to protect people already on treatment. But the form doesn't say what documentation proves that starting BMI. And some comorbidity questions are in the present tense, so if your prediabetes or blood pressure improved on the drug, it's unclear whether you still count. Think about who that is. Someone who turned sixty-five after a couple of years paying cash through a telehealth site, maybe on a compounded product, and whose old records live on a platform their new doctor can't see. The authors' worry: they stop, regain the weight, and only then qualify. Their closing line says successful treatment should not itself become an obstacle to continuity of care. I'd frame that on the wall. Their fixes are modest. CMS should spell out acceptable records, clarify whether comorbidities are judged at the start of therapy or at application, and set up a transition path. Disclosures matter here: Sullivan reports research support from Novo Nordisk and Eli Lilly, and Mattingly serves on a CMS advisory working group. If you're on Medicare and started a GLP-1 outside insurance, ask your prescriber now what records from that first prescription you can gather.
Bill Schiffner, writing in Chain Drug Review:
The survey of 256 U.S. pharmacists found that 54% have seen patients pay out of pocket for a GLP-1 prescription despite having access to a cheaper covered option through their insurance plan.
Which is the other half of the Bridge story. The survey is from Buzz Health, published Wednesday. Sixty-eight percent of pharmacists saw cash GLP-1 purchases rise over the past year, and sixty-one percent see someone pay cash for one every week while using insurance for everything else. Why? Forty-three percent pointed to manufacturer direct-to-consumer programs and telehealth pricing, and thirty-six percent to the new oral GLP-1s. Buzz Health's president, Joseph Kleiman, puts it as a known price, no prior authorization, and a faster path to the medication. Caveat: it's two hundred fifty-six pharmacists answering a company's survey. It tells you what pharmacists are seeing, not how many patients nationwide. Look at that list again, though. People will pay more just to skip the prior auth. That's not a consumer quirk; it's a review of the prior auth process. And the article flags the cost: every cash fill drops out of the claims record, so plans can't see adherence or outcomes for those patients. Kleiman calls the Bridge a test case: if a predictable fifty-dollar copay pulls people back to coverage, commercial plans should notice. If you're paying cash, tell your prescriber and your pharmacist anyway, so your medication list stays complete.
Lauren Pelley, reporting for CBC News:
For older youth from the age of 10 to 19, medical treatments may be considered only when a supervised lifestyle program hasn't achieved results, the guidance states, while bariatric surgery should only be an option under strict conditions for youth living with severe obesity.
These are the World Health Organization's first-ever international guidelines on managing childhood obesity, released Wednesday. Up to age nine, no medication, surgery or weight-loss devices. Ten and up, medication only after a supervised lifestyle program hasn't worked, with structured long-term follow-up. On Tuesday we covered the U.S. side of this: a Pediatrics study showing a three-hundred-ten-fold jump in GLP-1 prescriptions for kids eight to eleven. The WHO lands more cautiously. It calls the evidence on medications for childhood obesity, GLP-1s included, generally of low quality, citing short follow-up and small studies. I'd rather a global body say that out loud than pretend otherwise. But notice it isn't unanimous. Canada's 2025 guidance says GLP-1s from age twelve, and explicitly rejects the idea that you have to fail lifestyle treatment first. London, Ontario pediatric endocrinologist Dr. Marina Ybarra welcomes the WHO move because it might help win public funding. Right now Canadian kids mostly pay through a parent's insurance or out of pocket. Lifestyle first only works if the lifestyle program exists and someone pays for it. For scale, the WHO counts roughly a hundred seventy million kids and teens aged five to nineteen living with obesity in 2024, and prevalence in that group has quadrupled since 1990. If you're a parent weighing this, these guidelines are a good thing to bring to your child's pediatrician.
Local Chorus, summarizing Korean coverage including Yonhap:
Korea's Ministry of Food and Drug Safety approved Hanmi Pharmaceutical's EPPE auto-injector (efpeglenatide) on Oct 7, the first domestically developed GLP-1 obesity drug and the country's 45th homegrown new drug.
That was Wednesday, Seoul time. It's an injectable for chronic weight management in adults with obesity or overweight who don't have diabetes, approved at doses from two to ten milligrams. Yonhap describes Korea's market as split between Wegovy and Mounjaro, and reports Hanmi plans to launch within the year. What we don't have: a price, a launch date, or completed phase three results. The only efficacy numbers come from one Korean outlet, attributed to Hanmi's interim data, and the summary itself says they're hard to reconcile. Company-reported, interim, single source. That's three strikes for quoting them. A little history, though. The drug was licensed out to Sanofi in 2015 and handed back in 2020, and Hanmi kept going. Industry watchers there say it'll need to compete on price. More makers in this class is how prices eventually move, even if it starts far from here. For listeners in the U.S., nothing changes yet. The reporting mentions no U.S. plans, and this isn't something you can get here.
Got a question for us about anything in today's rundown, from second-eye risk to Bridge paperwork? Or did we miss something? Send it to glp1daily at lantern podcasts dot com. Listener notes shape what we chase next.
You'll find every source from today in the show notes. Thanks for spending your Thursday with GLP-1 Daily, a Lantern Podcast. We're back tomorrow.